Peptide Comparison
CagriSema vs Liraglutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Liraglutide has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Liraglutide is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| CagriSema | Liraglutide | |
|---|---|---|
| Class | Amylin + GLP-1 combination | GLP-1 receptor agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Dual amylin + GLP-1 receptor agonism | GLP-1R agonist; albumin-binding fatty acid extends half-life |
| Route | SC injection | SC injection |
| Half-life | ~7 days | ~13 hrs |
| Dosage (research) | 2.4 mg / 2.4 mg SC weekly | 0.6 mg SC daily (Victoza/Saxenda label starting dose, escalate weekly by 0.6 mg to 1.8 mg/day for T2D per Victoza or 3 mg/day for obesity per Saxenda label) |
| Evidence tier | Phase 3 | FDA-Approved |
| Research depth | 113 indexed | 321 indexed |
| Availability | Investigational | Prescription |
| Reported risks | GI effects; Phase 3 REDEFINE mixed results | Nausea; vomiting; pancreatitis; gallbladder disease; thyroid C-cell tumor warning |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CagriSema or Liraglutide?
Liraglutide has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Liraglutide is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between CagriSema and Liraglutide?
CagriSema is classed as Amylin + GLP-1 combination; Liraglutide is classed as GLP-1 receptor agonist. Reported mechanism: CagriSema, Dual amylin + GLP-1 receptor agonism; Liraglutide, GLP-1R agonist; albumin-binding fatty acid extends half-life. Reported half-life: CagriSema, ~7 days; Liraglutide, ~13 hrs. Routes in published studies: CagriSema, SC injection; Liraglutide, SC injection.
Which has stronger evidence, CagriSema or Liraglutide?
Liraglutide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies. Liraglutide is graded FDA-Approved, with 64 cited sources on its reference page and 321 indexed studies.
Which is more accessible, CagriSema or Liraglutide?
Liraglutide is FDA-approved and CagriSema is not. Catalog status: CagriSema, Investigational; Liraglutide, Prescription.
Are CagriSema and Liraglutide ever combined?
CagriSema and Liraglutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…